Long-term Patient-Centered Outcomes in Cirrhotic Patients With Chronic Hepatitis C After Achieving Sustained Virologic Response.

Journal Article (Clinical Trial;Journal Article)

Background & aims

Achieving sustained virologic response (SVR) among patients with hepatitis C virus (HCV) leads to patient reported outcome (PRO) improvement. We aimed to assess the long-term post-SVR PRO trends in HCV patients with cirrhosis.


Patients with HCV and cirrhosis treated in clinical trials with direct acting antiviral agents (DAAs) who achieved SVR-12 were prospectively enrolled in a long-term registry (clinicaltrials.gov #NCT02292706). PROs were collected every 24 weeks using the Short Form-36v2 (SF-36), CLDQ-HCV, and WPAI-HCV.


Pre-treatment baseline data were available for 854 cirrhotic patients who achieved SVR after DAAs. Of these, 730 had compensated (CC) and 124 had decompensated cirrhosis (DCC) before treatment- patients with DCC reported severe impairment in their PROs in comparison to CC patients (by mean -5% to -16% of a PRO range size; p < .05 for 16 out of 20 studied PROs]. After achieving SVR and registry enrollment, significant PRO improvements were noted from pre-treatment levels in 11/20 domains for those with DCC (+4% to +21%) and 19/20 PRO domains in patients with CC (+3% to +17%). Patients with baseline DCC had higher rates of hepatocellular carcinoma and mortality (P < .05). In patients with CC, the PRO gains persisted up to 168 weeks (3.5 years) of registry follow-up. In patients with DCC, the improvements lasted for at least 96 weeks but a declining trend after year 2.


Patients with HCV cirrhosis experience severe PRO impairment at baseline with sustainable improvement after SVR. Though those with DCC experience improvement, there is a decline after 2 years.

Full Text

Duke Authors

Cited Authors

  • Younossi, ZM; Racila, A; Muir, A; Bourliere, M; Mangia, A; Esteban, R; Zeuzem, S; Colombo, M; Manns, M; Papatheodoridis, GV; Buti, M; Chokkalingam, A; Gaggar, A; Nader, F; Younossi, I; Henry, L; Stepanova, M

Published Date

  • February 2022

Published In

Volume / Issue

  • 20 / 2

Start / End Page

  • 438 - 446

PubMed ID

  • 33493697

Electronic International Standard Serial Number (EISSN)

  • 1542-7714

International Standard Serial Number (ISSN)

  • 1542-3565

Digital Object Identifier (DOI)

  • 10.1016/j.cgh.2021.01.026


  • eng